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Objectives: The aim of this study was to analyze the 8-year expe-
rience, survival, prosthetic complications, and hemodynamics of
patients who received the Biocor valve, a new-generation tissue
valve, in the aortic position.
Methods: From May 1992 through May 2001, 257 consecutive
patients (129 women and 128 men; mean age, 75  6 years; age
range, 45-91 years) received 258 aortic Biocor porcine prostheses.
One female patient who received 2 Biocor valves in the aortic
position during 2 consecutive operations was entered twice in the
statistical analysis. Twelve (4.6%) patients had previous aortic
valve operations. Preoperatively, 82 (32%) patients were in New
York Heart Association functional class III or IV. Associated surgical procedures
included coronary artery bypass grafting in 56 (21.7%) patients, aortic annular
enlargement or aortoplasty in 20 (8%) patients, and others in 8 (3%) patients.
Echocardiography was performed in the majority of long-term survivors (91.6%).
Follow-up included 1215 patient-years and was 100% complete, with a median time
of 5 patient-years (range, 0.4-10.5 years).
Results: There were 16 (6.2%) early deaths. According to a univariate analysis,
New York Heart Association functional class III or IV, concomitant procedures,
ejection fractions of less than 40%, and urgent operations were identified as
significant perioperative risk factors. At follow-up, 75 patients died; 8-year
actuarial Kaplan-Meier survival was 48%  5%. At 8 years, the actuarial
freedom from valve-related death was 92%  2.6%, the freedom from throm-
boembolism was 93%  2%, the freedom from anticoagulant-related hemor-
rhage was 95%  2%, the freedom from endocarditis was 99%  0.6%, the
freedom from paravalvular leak was 96%  1.5%, the freedom from all
valve-related complications was 78%  4.5%, and the freedom from structural
valve deterioration was 95%  3.7%. At 8 years, the actuarial freedom from
structural valve deterioration was 89%  10% and 95.8%  4% in patients
younger and older than 65 years, respectively. At 10 years, in patients older than
65 years, the actual freedom from structural valve deterioration was 97.9% 
2.1%, and the freedom from reoperation was 97%  1.3%. New York Heart
Association status was I or II in 90% of patients at the end of follow-up. The
mean echocardiographic follow-up time was 4.6  2 years. By using Doppler
echocardiography, the peak and mean transprosthetic gradients were determined
to be 30.8  9.3 mm Hg and 16.6  5.3 mm Hg, respectively. Mean mass/
volume ratio and left ventricular end-diastolic volume were 1.37  0.17 g/mL
and 63.4  22.6 mL/m2, respectively. The majority of patients showed a
persistent left ventricular hypertrophy.
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Conclusion: The Biocor is an effective bioprosthesis with a low incidence of
valve-related complications comparable with that of other second-generation bio-
prostheses. This stented porcine prosthesis provides satisfactory results in terms of
hemodynamics, valve durability, and freedom from reoperation.
Second-generation tissue valves have been pro-cessed and engineered to enhance their dura-bility and their hemodynamic performancecompared with those of first-generation bio-prostheses. The Biocor prosthesis (Biocor In-dustria e Pesguisa Ltda, Belo Horizonte, Bra-
zil)1 is a triple-composite porcine tissue valve fixed in
glutaraldehyde at zero pressure (the so-called resting state)
and mounted on a flexible acetal copolymer (Celcon) stent.
This second-generation porcine valve has been used in our
institution since 1992 (Figure 1).
The aim of this study was to analyze the 8-year clinical
performance, complication rate, and hemodynamic perfor-
mance of the Biocor porcine bioprosthesis implanted in a
consecutive series of patients who underwent isolated aortic
valve replacement.
Patients and Methods
Between May 1992 and May 2001, 257 consecutive patients (129
women and 128 men; mean age, 75  6 years; median age, 75
years; age range, 45-91 years) underwent 258 isolated aortic heart
valve replacements at our institute. One female patient who re-
ceived 2 Biocor valves in the aortic position during 2 consecutive
operations was entered twice in the statistical analysis. The anal-
ysis was prosthesis oriented, and observations were censored when
the bioprosthesis was replaced. The patients’ data were prospec-
tively collected and updated in our prosthesis database. Patients’
demographic data are detailed in Table 1.
Thirty-two percent (82/258) of patients were in New York
Heart Association (NYHA) functional class III or IV. Twelve
(4.5%) patients had previously received a different prosthesis in
the aortic position. Concomitant procedures included coronary
revascularization (56/258), aortic annular enlargement or aorto-
plasty (20/258), and others (8/258). Mean aortic prosthetic size
was 23.6  1.8 mm (median, 23 mm; range, 21-27 mm). The
indexed effective orifice area was greater than 1 cm2/m2 in all
patients (mean, 2.24  0.4 cm2/m2; median, 2.10 cm2/m2; range,
1.6-4.0 cm2/m2), but there were 5 patients in whom the effective
orifice area was between 1 and 0.85 cm2/m2 (only 2 patients had
an indexed effective orifice area equal to 0.85 cm2/m2). Explanted
bioprostheses underwent pathologic examination, as previously
reported by our department for other valve types.2
Echocardiographic Analysis
Patients underwent 2-dimensional echocardiography to evaluate
hemodynamic results. The majority of surviving patients (153/167)
underwent 2 consecutive echocardiograms between June 2000 and
December 2002. We included in the analysis the hemodynamic
results of 10 patients who died some time after the first echocar-
diogram. The mean echocardiographic follow-up time was 4.6 
2 years. The simplified Bernoulli equation was used to calculate
mean and peak pressure gradients across the valve. Left ventricular
volumes were calculated by using an ellipsoid biplane area-length
method.3 Left ventricular myocardial mass was calculated by
multiplying the myocardial volume by the specific weight of
myocardial muscle (1.05 g/mL).4 The left ventricle was defined as
normal when the left ventricular end-diastolic volume was less
than 70 mL/m2 and the mass/volume ratio (M/V) was between 0.8
and 1.2 g/mL. The ejection fraction was calculated as follows:
(end-diastolic volume  end-systolic-volume)/end-diastolic vol-
ume.
Surgical Technique
Median sternotomy, cardiopulmonary bypass, moderate hypother-
mia, and aortic crossclamping were used in all patients. Cardiople-
gic arrest was achieved by using antegrade and retrograde cold
blood cardioplegia repeated at 20-minute intervals.
Aortic prostheses were implanted through a transaortic ap-
proach. Mean aortic crossclamp and cardiopulmonary bypass
times were 82  43 minutes and 113  38 minutes, respectively.
Prostheses were inserted by using multiple interrupted 2-0 Ticron
sutures reinforced by Teflon pledgets with the noneverted suturing
technique. Patients received continuous oral anticoagulation with
warfarin sodium (target international normalized ratio, 2.0-3.0).
The treatment is usually started on the second postoperative day
and continues until the third postoperative month. Patients with
chronic atrial fibrillation and patients with left atrial dilatation, left
ventricular dilatation, or both were anticoagulated indefinitely.
Patient Follow-up
Follow-up data were collected on an annual basis through direct
visits, questionnaires, or telephone interviews. Follow-up was
closed in December 2002, and the cumulative time was 1215
patient-years; it was 100% complete. Median and mean follow-up
time was 5 patient-years (range, 0.3-10.5 years).
Statistical Analysis
Edmunds and colleagues’5 guidelines for morbidity and mortality
reporting were used for definition of postoperative complications
and prostheses-related events.
The linearized rate of postoperative complications and prosthe-
ses-related events was expressed as percentage per patient-year.
The 2 test was used for statistical comparisons.
The estimate of overall survival was calculated by use of the
Kaplan-Meier method and expressed as percentage  SE or per-
centage  95% confidence interval. The 65-year-old patients were
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included in the group of patients older than 65 years. We consider
our data informative up to 8 years, with 21 patients at risk.
Actual freedom from complication was calculated by using the
method of Grunkemeier and associates.6
Results
Sixteen (6.2%) patients, 10 women and 6 men (mean age,
76.6  1 years; age range, 71-83 years), died periopera-
tively (30 days). Sixty percent were in NYHA class III or
IV, 25% had an urgent operation, and 50% had a concom-
itant procedure (1 with ventricular septal defect, 1 with
aortoplasty, and 6 with coronary artery disease), and in 30%
the ejection fraction was less than 40%. NYHA class III or
IV, concomitant procedures, low ejection fractions, and
urgent operations were identified as significant univariate
risk factors (P  .05). Causes of death are detailed in Table
2.
Survival
Overall 8-year survival was 48%  5% (Figure 2). There
were 75 (31%) late deaths: 21 (28%) were cardiac related,
and 14 (18%) were valve related. Actuarial freedom from
valve-related death was 92%  2.6% at 8 years (linearized
rate of 1.1%/patient-year, Table 3). Causes of late death are
detailed in Table 2. At the end of follow-up, 90% of patients
were in functional class I or II, 80% of patients were
anticoagulated, and 67% were in sinus rhythm. Therefore
92% of surviving patients improved or remained function-
ally stable, and 8% of patients had a worsening of functional
status.
Thromboembolism
Twelve major thromboembolic events occurred in 11 pa-
tients, 1 early and 11 late (linearized rate of 0.9%/patient-
year). Among these patients, 64% had an embolic stroke
before surgical intervention, 62% were in atrial fibrillation,
and 75% were anticoagulated. Embolism was fatal in 6
patients, causing 1 early and 5 late deaths. Prosthetic throm-
bosis was the cause of a late death in an 84-year-old woman
affected by chronic atrial fibrillation and bearing patient-
prosthesis mismatch. Actuarial freedom from thromboem-
bolism and thrombosis was 93%  2% at 8 years (Table 3).
Hemorrhagic Events
Six patients had anticoagulation-related major hemorrhage,
which was fatal in 4 cases; the linearized rate was 0.5%/
Figure 1. Unimplanted aortic Biocor valve.
TABLE 1. Demographics
Variables Value
Prostheses 258
Age, y (mean  SD; median; range) 75 6; 75; 45-91
Male/female sex 128 (49.6%)/130 (50.4%)
Sinus rhythm 235 (91%)
Atrial fibrillation 16 (6%)
Pacemaker because of heart block 8 (3%)
NYHA class I-II 193 (75%)
NYHA class III-IV 65 (25%)
Aortic stenosis 186 (72.1%)
Aortic incompetence 30 (11.6%)
Mixed lesion 42 (16.3%)
Stroke before the operation 6 (2.3%)
Mean pulmonary pressure 30 mm Hg 26 (10%)
Left ventricular function 40% 26 (10%)
Chronic obstructive pulmonary disease 15 (6%)
Active endocarditis 1 (0.4%)
Previous endocarditis 2 (0.8%)
Previous aortic valve surgery 12 (4.6%)
Urgent surgery* 10 (4%)
Associated procedure
Coronary disease 56 (22%)
Aortic annulus enlargement or
aortoplasty
20 (8%)
Others 8 (3%)
*Within 48 hours from hospital admission.
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patient-year. Eight-year actuarial freedom from anticoagu-
lant-related hemorrhage was 95%  2% (Table 3).
Paravalvular Leak
Seven patients who underwent aortic valve replacement
because of a bicuspid aortic valve (1 patient), calcific de-
generative valve stenosis (5 patients), and subacute native
valve endocarditis (1 patient) had a paravalvular leak. The
linearized rate was 0.66%/patient-year. Six of these patients
underwent reoperation. The mean interval between implan-
tation and paravalvular leak was 1.26  2 years (median
interval, 0.5 years). Eight-year actuarial freedom from leak
was 96%  1.5% (Table 3).
Endocarditis
Two patients had endocarditis, and they were medically
treated (linearized rate of 0.16%/patient-year). Actuarial
freedom from endocarditis was 99%  0.6% at 8 years
(Table 3).
Structural Valve Deterioration
Structural valve deterioration (SVD) occurred in 3 patients
(linearized rate of 0.24%/patient-year). The first case of
SVD occurred in a 53-year-old man who underwent a
prosthetic replacement after 5.5 years, and the second and
the third cases of SVD occurred in 58- and 78-year-old men
who had received the Biocor valve 8 and 9 years earlier,
respectively. In both cases the diagnosis was based on
echocardiography, but their general clinical status contrain-
dicated a new valve operation. Overall 8-year actuarial
freedom from SVD was 95%  3.7%. According to age,
8-year actuarial freedom from SVD was 89%  10% in
patients younger than 65 years of age and 96%  4% in
patients older than 65 years (P  .004, log-rank test; Figure
3). Overall 10-year actual freedom from SVD was 90.3%
6.8% (Figure 4), and it was 97.9%  2.1% in patients older
than 65 years.
Reoperations
Eight patients underwent reoperation; the linearized rate
was 0.66%/patient-year. Most reoperations (75%) were per-
formed on the first postimplantation year. Eight-year actu-
arial (Table 3) and actual freedoms from reoperation were
95%  1.8% and 96.1%  1.4%, respectively. In patients
younger than 65 years, the reoperation causes were SVD (1
patient) and paravalvular leak (1 patient). In older patients
left ventricular outlet obstruction (1 patient) and paravalvu-
lar leak (5 patients) were the causes. Actual 8-year freedom
from reoperation was 85.4%  9.6% in patients younger
than 65 years and 97%  1.3% in patients older than 65
years.
Valve-Related Complications
There were 35 valve-related complications in 34 patients,
including hemorrhage, thromboembolism, thrombosis, en-
docarditis, paravalvular leak, SVD, and sudden death. The
linearized rate was 2.8%/patient-year. Actuarial freedom
from valve-related complication was 78% 4.5% at 8 years
(Table 3).
Echocardiography
Doppler echocardiographic data are summarized in Table 4
according to valve size. Mean and peak transprosthetic
gradients for all valves were 16.6  5.3 mm Hg and 30.8 
9.3 mm Hg, respectively. By grouping prosthetic size
(21-27 mm, 23-27 mm, and 25-27 mm), the mean and peak
gradients were significantly related to smaller size. The
mean ejection fraction value was 60.1  9.5. Average body
surface area was 1.73  0.16 m2. Valve size was signifi-
cantly related to body surface area. The mean values of the
M/V ratio and left ventricular end-diastolic volume were
1.37  0.17 g/mL and 63.4  22.6 mL/m2, respectively.
The majority of patients (83.6%) had an M/V ratio of
greater than 1.2 g/mL. In the 5 patients with an indexed
effective orifice area of less than 1 cm2/m2, the echocardio-
gram showed an M/V ratio of 1.39 g/mL, and the difference
between these few patients and the entire population was
not significant (P  .82).
Discussion
In the time interval of this study, 455 tissue valves (Biocor
and Carpentier-Edwards Perimount) were implanted in the
isolated aortic position by all the surgeons of our unit. Our
indications for the use of bioprostheses were usually iden-
tical to those reported by the American Heart Association.7
Nonetheless, the final choice was up to the surgeon, depend-
ing on operative table findings. This study summarizes our
experience with the use of the Biocor porcine prosthesis
implanted in the aortic position.
TABLE 2. Cause of death
Cause No.
Early deaths: 16 patients (6.2%)
Cardiac related 7 (44%)
Neurologic 2 (12%)
Cerebral embolism 1 (6.5%)
Respiratory failure 2 (12%)
Sudden 3 (19%)
Other 1 (6.5%)
Late deaths: 75 patients (31%), 6.2%/patient-year
Cardiac related (1.7%/patient-year) 21 (28%)
Thrombosis (0.08%/patient-year) 1 (1%)
Thromboembolism (0.4%/patient-year) 5 (6.6%)
Cerebral hemorrhage (0.3%/patient-year) 4 (5%)
Sudden (0.3%/patient-year) 4 (5%)
Other noncardiac (3.3%/patient-year) 40 (53%)
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Calcification was the major cause of failure of the first-
generation porcine bioprosthesis (70%-80%), whereas pri-
mary cusp tearing was the major cause of failure of the
first-generation pericardial bovine bioprosthesis (80%-
90%).8-13 Therefore improvements were introduced in both
tissue valve models to enhance their long-term perfor-
mance. The Biocor prosthesis is a new-generation porcine
valve, introduced on the market in 1982, composed of 3
different cusps mounted in a Celcon stent, covered by
Dacron fabric, and fixed with glutaraldehyde at zero pres-
sure.1 At our institute, the clinical use of the Biocor valve
began in 1992, and intermediate14 and long-term15 results
comparable with those observed with the Hancock II16 and
Carpentier-Edwards17 pericardial prostheses have been ob-
served.
Clinical Results
Compared with the 65% 8-year survival of the sex- and
age-matched Italian population (1999 census data), the sur-
vival of the aortic patients of this series was significantly
lower (P  .001). Compared with our results with the
Hancock II prosthesis (a second-generation porcine
valve),18 we observed a lower survival with the Biocor
valve, most probably related to the 8-year older average age
of the Biocor patients (P  .05). Similarly, several other
series performed with different tissue valves, either first-
and second-generation porcine prostheses or second-gener-
ation pericardial prostheses,15-17,19-22 apparently reported
better survivals than ours. However, we stress that in these
comparisons our results are penalized by the older popula-
tion age and by the small number of patients at risk at the
end of follow-up, which in our series was 21 patients at 8
years and decreased to 4 patients at 10 years.
The confounding effect of older operative age on sur-
vival is well illustrated by comparing our results with those
obtained with Carpentier-Edwards Perimount prostheses
and published by Dellgren and colleagues.21 These authors
report excellent survival at 10 years (50% 8%; 10 patients
at risk at 10 years) by analyzing a population similar to our
series in number (254 patients vs 258 patients) and with
female prevalence (54% vs 50.3%) but with significantly
younger patients (mean age, 71.3 years vs 75 years; P 
.05).
In our series the majority of patients had mild left ven-
tricular hypertrophy, including the 5 patients with an in-
dexed effective orifice area of between 1 and 0.85 cm2/m2.
Among these, only 2 patients definitely had a mismatch
according to the Pibarot criteria.23 We observed a single late
Figure 2. Ten-year actuarial survival. Dotted lines depict confidence interval.
TABLE 3. Overall 8-year Kaplan-Meier freedom from valve-
related events
Valve-related death 92% 2.6%
Paravalvular leak 96% 1.5%
Reoperation 95% 1.8%
Thromboembolism 93% 2%
Endocarditis 99% 0.6%
Major bleeding 95% 2%
Valve-related mortality and morbidity 78% 4.5%
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death among these 5 patients, and the cause of death was a
valve thrombosis, which cannot be related to the hypertro-
phy-arrhythmia complex of mismatch. Aortic root enlarge-
ment procedures are suggested in this clinical setting; how-
ever, Carrier and associates24 and Sommers and
coworkers25 observed that after such procedures, the oper-
ative mortality is twice that observed with standard aortic
valve replacement. Recently, Freed and colleagues26 re-
Figure 3. Eight-year actuarial freedom from SVD according to age.
Figure 4. Ten-year actual freedom from SVD. Circles depict confidence interval.
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ported normalization of left ventricular mass in elderly
women who received a small aortic valve (19 mm), sug-
gesting care should be taken with the more complex proce-
dures. In our Biocor series the aortic annulus enlargement
procedure, which was done in 8 patients, was without com-
plications; nonetheless, similarly neither the presence of
prosthesis-patient mismatch nor the presence of a small
prosthesis were risk factors for death. This finding mitigates
the utility of aortic root enlargement, especially in small old
ladies with a high risk of bleeding, in case of minimal
technical errors.
Comparing our hemodynamics with those obtained with
the Carpentier-Edwards Pericardial valve,21 under the same
left ventricular function, peak and mean gradients were
significantly lower with the pericardial bioprostheses (P 
.05). These data might explain why two thirds of our pa-
tients had a persistent mild left ventricular hypertrophy
compared with one third of patients receiving pericardial
valves. It is obvious that all stented tissue valves, including
Hancock II, Biocor, and Carpentier-Edwards (either peri-
cardial21 or supra-annular porcine valves27) have inferior
hemodynamics when compared with those of the stentless
bioprostheses.28,29 This hemodynamic advantage does not
necessarily translate into a survival advantage.30-33 Luciani
and associates34 reported superior results in terms of sur-
vival and event-free survival in favor of the stentless valve.
Nevertheless, we stress that in this study the age of the
patients receiving stentless valves was significantly
younger. Therefore we continue to favor the use of stented
bioprostheses because we believe that the significantly
longer aortic crossclamp and cardiopulmonary bypass times
of their stentless group might adversely affect early and late
survival of a population as old as their stented one.
Overall freedom from valve-related complications is
comparable with that obtained with last-generation porcine
and pericardial tissue valves by Myke´n and coworkers,15
David and associates,16 Banbury and colleagues,19 and Le
Tourneau and associates35 with Biocor, Hancock II, Car-
pentier-Edwards pericardial, and Carpentier-Edwards su-
pra-annular porcine valves, respectively. In detail, our
thromboembolism and anticoagulant-related hemorrhage
rates are comparable with those reported by other au-
thors.15-22 Similarly, endocarditis and thrombosis were very
rare.
The linearized incidence of paravalvular leaks (0.66%
patient-years; 7 patients) was similar to that observed by
Myke´n and coworkers15 with the same valve. In the litera-
ture there is a wide range of rates of this complication,
which is related to several patient and surgeon factors.
Freedom From SVD
We observed 3 patients with SVD. Only 1 patient was older
than 65 years, and only 1 patient has undergone reoperation.
The minimum interval between implantation and SVD ap-
pearance was 5.5 years, but the patient who had the shortest
interval was 53 years old. The other 2 patients showed
echocardiographic signs of SVD 8 and 9 years after implan-
tation.
In the entire series 10-year actual SVD freedom was
90.3%, whereas in patients older than 65 years, it was
97.9%. Therefore young age is a durability risk factor, as
previously stated by others,16,18-20 and Biocor valves make
no exception to this rule. Our 10-year actual freedom from
SVD matches closely with that obtained with other second-
generation bioprostheses (Hancock II and Carpentier-Ed-
wards pericardial and supra-annular porcine bioprosthe-
ses).16,18-20,22
Freedom From Reoperation
Actual freedom from reoperation because of SVD was
excellent in patients older than 65 years, a finding compa-
rable with that observed with Hancock II and Carpentier-
Edwards pericardial valves,16,19 but 7 reoperations were
required because of paravalvular leak. The rate of this
complication was disturbing. We blame the severely calci-
fied and frail aortic annulus tissue of elderly patients; none-
theless, as previously pointed out by Myke´n and cowork-
ers,15 the very narrow Biocor valve sewing ring could also
be blamed.
In conclusion, this clinical experience shows that the
Biocor porcine prosthesis guarantees results similar to those
obtained with other second-generation prostheses in term of
hemodynamics, valve durability, and freedom from reop-
eration.
We thank Di Marco Francesca, MD, for his assistance in
preparing the echocardiogram data collection.
TABLE 4. Echocardiographic data
Valve size
(mm)
No. of
patients
Peak gradient
(mm Hg)
Mean gradient
(mm Hg) EF (%) M/V (g/mL)
LVEDV
(mL/m2) BSA (m2)
21 27 35 9 19.6 6.3 63 8 1.38 0.17 63 17 1.6 0.13
23 67 30.6 8 16.6 4.7 61 9.4 1.36 0.14 60 18 1.7 0.14
25 45 31.7 9 16.5 4.3 59 9 1.38 0.18 66 30 1.8 0.15
27 14 21 9 11 4.5 54 11 1.35 0.26 72 27 1.9 0.13
EF, Ejection fraction; M/V, mass/volume ratio; LVEDV, left ventricular end-diastolic volume; BSA, body surface area.
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